Of clinical significance, both lovastatin and metformin induce synergistic cytotoxicity in combination with the EGFR inhibitor gefitinib in LKB1 expressing tumour cells, however likely due to its ability to activate multiple metabolic stress pathways; lovastatin also induced synergy with gefitinib in LKB1 deficient tumours. Here, EGFR is linked to neoplasm.